Trial Profile

An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose LY3884961 in Infants With Type 2 Gaucher Disease

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PR 001 (Primary) ; Methylprednisolone; Prednisone; Sirolimus
Indications Gaucher's disease type II
Focus Adverse reactions; Pharmacodynamics
Acronyms PROVIDE
Sponsors Prevail Therapeutics

Most Recent Events

19 Mar 2024 Planned End Date changed from 1 Dec 2028 to 1 May 2028.
19 Mar 2024 Planned primary completion date changed from 1 Dec 2028 to 1 May 2028.
22 Jan 2024 Planned End Date changed from 1 Sep 2028 to 1 Dec 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com